INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Effects of fertility drugs on cancers other than breast and gynecologic malignancies.

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/20541

Files in this item

File Description Format
PDF Effects of Fertility Drugs.pdf (143KB) Manuscript PDF
Title: Effects of fertility drugs on cancers other than breast and gynecologic malignancies.
Author(s): Brinton, LA; Moghissi, KS; Scoccia, B; Lamb, E; Trabert, B; Niwa, S; Ruggieri, D; Westhoff, CL
Subject(s): Cancer clomiphene citrate gonadotropins infertility risk
Abstract: Abstract OBJECTIVE: To examine the relationship of ovulation-stimulating drugs to risk of cancers other than breast and gynecologic malignancies. DESIGN: Retrospective cohort study, with additional follow-up since initial report. SETTING: Reproductive endocrinology practices. PATIENT(S): Among a cohort of 12,193 women evaluated for infertility between 1965 and 1988, a total of 9,892 women (81.1% of the eligible population) were followed through 2010, via passive and active (questionnaire) approaches. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Hazard ratios (HRs) and 95% confidence intervals (CIs) for various fertility treatment parameters for select cancers. RESULT(S): During 30.0 median years of follow-up (285,332 person-years), 91 colorectal cancers, 84 lung cancers, 55 thyroid cancers, and 70 melanomas were diagnosed among study subjects. Clomiphene citrate (CC), used by 38.1% of patients, was not associated with colorectal or lung cancer risks, but was related significantly to melanoma (HR = 1.95; 95% CI: 1.18-3.22), and non-significantly to thyroid cancer risks (HR = 1.57; 95% CI: 0.89-2.75). The highest melanoma risks were seen among those with the lowest drug exposure levels, but thyroid cancer risk was greatest among the heavily exposed patients (HR = 1.96; 95% CI: 0.92-4.17 for those receiving >2,250 mg). Clomiphene citrate-associated risks for thyroid cancer were somewhat higher among nulligravid, compared with gravid, women, but did not differ according to distinct causes of infertility. Gonadotropins, used by only 9.7% of subjects, were not related to risk of any of the assessed cancers. CONCLUSION(S): Our results provide support for continued monitoring of both melanoma and thyroid cancer risk among patients receiving fertility drugs.
Issue Date: 2015-10
Publisher: Elsevier
Citation Info: Brinton, L. A., Moghissi, K. S., Scoccia, B., Lamb, E. J., Trabert, B., Niwa, S., Ruggieri, D. and Westhoff, C. L. Effects of fertility drugs on cancers other than breast and gynecologic malignancies. Fertility and Sterility. 2015. 104(4): 980-988. DOI: 10.1016/j.fertnstert.2015.06.045.
Type: Article
Description: This is the author’s version of a work that was accepted for publication in Fertility and Sterility. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Fertility and Sterility. 2015. 104(4): 980-988. DOI: 10.1016/j.fertnstert.2015.06.045.
URI: http://hdl.handle.net/10027/20541
ISSN: 0015-0282
Sponsor: Grant Support: Z01 CP010126-12/Intramural NIH HHS/United States.
Date Available in INDIGO: 2016-11-10
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
China 67
United States of America 67
Russian Federation 26
Germany 6
United Kingdom 6

Browse

My Account

Information

Access Key